204
Participants
Start Date
August 18, 2025
Primary Completion Date
June 30, 2026
Study Completion Date
November 30, 2026
68Ga-PSMA-11
The radioconjugate 68Ga-PSMA-11 is composed of a human PSMA-targeting ligand peptide conjugated via the acyclic radiometal chelator, N, N'-bis \[2-hydroxy-5-(carboxyethyl)benzyl\] ethylenediamine-N, N'-diacetic acid (HBED-CC) to the radioisotope Gallium68 ( 68Ga); which binds to PSMA on the surface of cells expressing PSMA, including malignant prostate cancer cells, which usually overexpress PSMA. 68Ga is a β+ (beta) ray emitting radionuclide that allows precise imaging via PET.
RECRUITING
Australian Prostate Centre, Melbourne N.
Telix Innovations S.A.
UNKNOWN
Telix Pharmaceuticals (Innovations) Pty Limited
INDUSTRY